Animal Model Market By Animal Type (Mice, Rats, Pigs, Non-Human Primates, Others); By Application (Toxicology Testing, Disease Research, Drug Discovery, Others); By End User (Pharmaceutical Companies, Biotechnology Firms, Academic and Research Institutions, CROs); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Animal Model Market is set to expand from USD 2.5 billion in 2024 to USD 4.5 billion by 2030, registering a 10.5% CAGR, supported by rising demand for CRISPR gene editing, laboratory animal models, neuroscience research, immunology studies, drug safety assessment, and precision medicine research, based on insights by Strategic Market Research.

 

The increasing need for animal models in scientific research and the growing focus on innovative therapeutics are some of the key factors driving market expansion. Animal models are crucial for drug discovery, biological research, and disease modeling, allowing researchers to better understand the mechanisms of diseases, evaluate potential treatments, and assess the safety of new drugs.

 

Technological advancements in genetic modification, a rising demand for personalized medicine, and improvements in animal welfare regulations are further fueling the market's growth. The push towards more ethical, effective, and cost-efficient alternatives to traditional research methods is expected to shape the landscape through 2030. Additionally, the increasing prevalence of chronic diseases, such as cancer, neurological disorders, and cardiovascular diseases, further emphasizes the relevance of animal models in advancing medical research.

 

Key stakeholders in the market include research institutions, biotechnology companies, pharmaceutical companies, contract research organizations (CROs), and governments. These players collaborate to develop advanced animal model solutions, ensuring compliance with ethical standards while striving to meet the growing demands of scientific research.

 

Expert Insight: The growing focus on in-vitro alternatives, while promising, will not entirely replace the need for animal models in the foreseeable future. The challenge will be balancing the development of humane, high-fidelity models with research efficacy.

 

Comprehensive Market Snapshot

The Global Animal Model Market is projected to grow at a 10.5% CAGR, expanding from USD 2.5 billion in 2024 to USD 4.5 billion by 2030, supported by increasing investments in CRISPR gene editing, laboratory animal models, neuroscience research, immunology studies, drug safety assessment, and precision medicine initiatives, according to Strategic Market Research.

• USA Animal Model Market held the largest regional share of 46% in 2024, valued at USD 1.15 billion, and is projected to reach approximately USD 1.97 billion by 2030 at a 9.4% CAGR.

• Europe Animal Model Market accounted for 22% of the global market in 2024, estimated at USD 0.55 billion, and is expected to reach around USD 0.89 billion by 2030 at an 8.3% CAGR.

• APAC Animal Model Market represented 13% of the global market in 2024, valued at USD 0.33 billion, and is projected to grow to approximately USD 0.69 billion by 2030 at a strong 13% CAGR, making it the fastest-growing region during 2024–2030.

 

Regional Insights

• USA accounted for the largest market share of 46% in 2024.

• APAC is expected to expand at the fastest CAGR during 2024–2030.

 

By Animal Type

• Mice dominated the global market with a 52% share in 2024, equivalent to approximately USD 1.30 billion, driven by their extensive use in genetic engineering and pharmacological studies.

• Rats accounted for an 18% share in 2024, valued at about USD 0.45 billion, supported by their widespread application in toxicology and behavioral research.

• Pigs held a 10% share in 2024, representing nearly USD 0.25 billion, owing to their physiological similarities to humans in translational research.

• Non-Human Primates captured an 8% share in 2024, amounting to roughly USD 0.20 billion, and are projected to grow at a notable CAGR through 2030 due to increasing complexity in neurological and translational research.

• Others comprised 12% of the global market in 2024, corresponding to approximately USD 0.30 billion, including species used for specialized and niche research applications.

 

By Application

• Disease Research accounted for the highest share of 40% in 2024, equivalent to approximately USD 1.00 billion, supported by oncology, neurology, and cardiovascular research programs.

• Drug Discovery represented 30% of the market in 2024, valued at about USD 0.75 billion, and is expected to grow at a strong CAGR through 2030, fueled by expanding biologics pipelines and precision therapeutics.

• Toxicology Testing held a 20% share in 2024, representing nearly USD 0.50 billion, driven by regulatory safety requirements and preclinical evaluation studies.

• Others accounted for 10% of the market in 2024, corresponding to approximately USD 0.25 billion, including education and specialized experimental applications.

 

By End User

• Pharmaceutical Companies contributed the largest share of 48% in 2024, equivalent to approximately USD 1.20 billion, reflecting strong reliance on preclinical testing and regulatory studies.

• Biotechnology Firms held a 22% share in 2024, valued at about USD 0.55 billion, and are anticipated to expand at a robust CAGR through 2030, supported by innovation in gene-editing and cell-based therapy development.

• Academic and Research Institutions accounted for 20% of the market in 2024, representing nearly USD 0.50 billion, driven by government and private research funding initiatives.

• CROs comprised 10% of the market in 2024, corresponding to approximately USD 0.25 billion, supported by outsourcing trends in preclinical and contract research services.

 

Strategic Questions Driving the Next Phase of the Global Animal Model Market

1. What species, research applications, and service components are explicitly included within the Global Animal Model Market, and which in vitro or organ-on-chip alternatives fall outside its scope?

2. How does the Animal Model Market differ structurally from adjacent preclinical testing, contract research, cell-based assay, and in silico modeling markets?

3. What is the current and projected size of the Global Animal Model Market, and how is value distributed across species categories and research applications?

4. How is revenue allocated between genetically modified models, inbred/standard models, and humanized animal models, and how is this mix expected to evolve over the forecast period?

5. Which application areas (e.g., oncology, immunology, neuroscience, cardiovascular, infectious diseases) account for the largest and fastest-growing revenue pools?

6. Which segments generate disproportionately higher margins, such as specialized transgenic or humanized models, compared to standard laboratory animal supply?

7. How does demand vary across early-stage discovery, preclinical safety assessment, and translational research, and how does this influence model selection?

8. How are CRISPR-based gene editing and advanced transgenic technologies reshaping competitive dynamics within animal model development?

9. What role do breeding cycles, customization timelines, and long-term colony management play in recurring revenue and client retention?

10. How are global disease prevalence trends, R&D funding flows, and biotech startup formation rates influencing demand across animal model segments?

11. What ethical regulations, animal welfare standards, and institutional review requirements constrain adoption or expansion in certain geographies?

12. How do pricing structures, research grant funding, and procurement contracts impact revenue realization across academic, pharmaceutical, and CRO end-user segments?

13. How robust is the current innovation pipeline in genetically engineered and disease-specific models, and which emerging research domains are likely to create new growth segments?

14. To what extent will advancements in alternative research platforms (e.g., organoids, AI-driven simulation) complement versus substitute traditional animal models?

15. How are improvements in breeding efficiency, genetic validation, and model reproducibility enhancing research accuracy and customer value?

16. How will consolidation among contract research organizations and laboratory animal suppliers reshape competitive positioning within the market?

17. What role will regional breeding hubs and localized supply chains play in reducing costs and improving accessibility in emerging markets?

18. How are leading companies aligning their portfolios across species, genetic platforms, and service offerings to defend or expand market share?

19. Which geographic markets are expected to outperform global growth in the Animal Model Market, and which research segments are driving this acceleration?

20. How should research institutions, pharmaceutical companies, and investors prioritize specific species categories, technology platforms, and regions to maximize long-term strategic value?

 

Segment-Level Insights and Market Structure

Animal Model Market

The Animal Model Market is structured around species categories, research applications, genetic platforms, and end-user groups, each reflecting distinct scientific objectives, regulatory requirements, and funding structures. Unlike therapeutic markets driven by patient treatment volumes, this market is shaped by research intensity, grant cycles, drug development pipelines, and innovation in genetic engineering technologies.

Each segment contributes differently to overall revenue, margin profile, and long-term growth potential. Standard laboratory models provide recurring volume-based demand, while specialized and genetically engineered models command premium pricing and strategic value in translational and precision research programs.

 

Animal Type Insights

Mice

Mice represent the cornerstone of the global animal model ecosystem. Their dominance is rooted in genetic similarity to humans, short reproductive cycles, well-characterized genomes, and compatibility with gene-editing tools such as CRISPR. From a commercial standpoint, mice account for the largest volume and revenue share due to their widespread use in oncology, immunology, metabolic disorders, and neuroscience research.

The segment benefits from strong repeat demand, as pharmaceutical and biotechnology companies frequently require customized strains tailored to specific molecular pathways. As precision medicine expands, demand for transgenic and knockout mouse lines continues to strengthen.

Rats

Rats occupy a strategically important position in toxicology, pharmacokinetics, and behavioral neuroscience research. Compared to mice, rats are often preferred in studies requiring more complex physiological assessments or larger sample volumes.

Commercially, the rat segment is characterized by stable demand from regulatory safety testing and long-standing use in drug metabolism studies. Although growth rates may be moderate relative to genetically modified mice, rats remain integral to early-stage safety evaluation and translational research.

Pigs

Pigs are increasingly utilized in advanced translational and surgical research due to anatomical and physiological similarities to humans. Their relevance is particularly strong in cardiovascular, metabolic, dermatological, and organ transplantation studies.

This segment commands higher per-unit pricing due to breeding complexity, housing requirements, and specialized care. Growth is driven by regenerative medicine and device testing applications, positioning pigs as a high-value niche within the broader market.

Non-Human Primates

Non-human primates (NHPs) are used in highly specialized research areas, including neuroscience, infectious diseases, and vaccine development. Their genetic proximity to humans makes them essential for late-stage translational studies when regulatory or scientific rigor demands higher biological similarity.

Although this segment represents a smaller share of overall volume, it contributes disproportionately to revenue due to premium pricing, strict regulatory controls, and specialized infrastructure requirements. Ethical oversight and supply limitations significantly influence market dynamics within this category.

Other Species

Other species, including zebrafish, rabbits, guinea pigs, and emerging alternative organisms, serve niche research needs. Zebrafish, for example, are gaining traction in developmental biology and high-throughput screening environments.

These models support diversification of research platforms and may benefit from increased demand for cost-effective and ethically adaptable research options.

 

Application Insights

Disease Research

Disease research represents the largest application segment, encompassing oncology, autoimmune disorders, neurological diseases, cardiovascular conditions, and rare genetic disorders.

Animal models in this segment are used to replicate disease pathophysiology, validate therapeutic targets, and assess treatment efficacy. As global R&D spending rises and biologics pipelines expand, disease-focused models—particularly humanized and genetically engineered variants—are expected to remain central to revenue growth.

Drug Discovery

Drug discovery applications span early target validation, lead optimization, and preclinical development. This segment benefits from rising pharmaceutical innovation and increasing biotech startup activity.

Commercially, drug discovery demand is closely linked to pipeline intensity. Companies often require multiple iterations of model refinement, supporting recurring contracts and collaborative development agreements.

Toxicology Testing

Toxicology testing remains a regulatory-driven application segment. Animal models are used to evaluate safety profiles, dose-response relationships, and organ-specific toxicity prior to clinical trials.

Although alternative in vitro approaches are expanding, regulatory frameworks in many regions still require animal-based safety data. This ensures continued relevance of the segment, particularly for systemic and biologic drug candidates.

Other Research Applications

Additional applications include vaccine research, stem cell studies, gene therapy validation, and medical device testing. These areas contribute incremental growth and reflect diversification in biomedical research priorities.

 

End-User Insights

Pharmaceutical Companies

Pharmaceutical companies represent the largest revenue-generating end-user group. Their reliance on animal models spans the full preclinical lifecycle—from target identification to safety validation.

Revenue contribution from this segment is characterized by high-value contracts, long-term supply agreements, and collaborative development of custom genetic models. As drug pipelines expand into complex biologics and gene therapies, pharmaceutical demand for specialized models is expected to intensify.

Biotechnology Firms

Biotechnology firms form a fast-growing customer base, particularly in gene editing, cell therapy, and precision medicine domains.

These companies often require customized or niche models to validate innovative mechanisms of action. Although contract sizes may be smaller than large pharmaceutical players, growth rates in this segment are typically higher due to rapid innovation cycles.

Academic and Research Institutions

Academic institutions and publicly funded research centers contribute substantial volume demand, particularly for standard laboratory strains.

Funding cycles, grant availability, and public health priorities heavily influence purchasing patterns. This segment supports foundational research that often precedes commercial drug development.

Contract Research Organizations (CROs)

CROs serve as intermediaries, conducting outsourced preclinical studies on behalf of pharmaceutical and biotech clients.

As outsourcing trends increase, CRO demand for reliable, scalable animal model supply is expected to grow. This segment supports recurring volume and enhances market resilience during periods of R&D restructuring.

 

Segment Evolution Perspective

The Animal Model Market is transitioning from a volume-driven supply model toward a value-driven, innovation-oriented structure.

Standard species continue to anchor baseline demand, while genetically engineered and humanized models are reshaping the revenue mix. Concurrently, outsourcing trends and integrated service platforms are redistributing value across supply channels.

Over the forecast horizon, growth is expected to be concentrated in advanced genetic platforms, precision disease models, and high-complexity translational applications. Ethical regulation, funding allocation, and alternative research technologies will remain critical factors influencing segment-level evolution and competitive positioning.

 

Market Segmentation And Forecast Scope

The animal model market is segmented based on several key factors, including animal type, application, end-user, and region. These segments allow for a deeper understanding of the factors driving market growth and help in forecasting potential trends.

By Animal Type

The animal type segment includes the primary species used in scientific research, including mice, rats, pigs, non-human primates, and other small animals. Among these, mice are expected to hold the largest market share in 2024, driven by their widespread use in genetic research and pharmacology. Mice are particularly valued for their ability to be genetically modified, enabling the creation of more accurate disease models.

Expert Insight: While mice remain dominant, the use of larger animals like pigs and non-human primates is expected to grow due to the increasing complexity of human disease models.

 

By Application

The application segment of the animal model market is divided into several key areas, including toxicology testing, disease research, drug discovery, and others. Disease research, particularly for chronic diseases such as cancer, neurological disorders, and cardiovascular diseases, is anticipated to witness the highest growth rate during the forecast period. Researchers require animal models to study the pathogenesis and treatment of these diseases in a controlled environment.

 

By End-User

Key end-users in the market include pharmaceutical companies, biotechnology companies, academic and research institutions, and contract research organizations (CROs). Among these, pharmaceutical companies are expected to be the largest contributors to the market's revenue, as they use animal models extensively for drug development and efficacy testing.

 

By Region

Geographically, the market is divided into North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa). North America is expected to hold the largest market share in 2024 due to the presence of major pharmaceutical and biotechnology companies, robust research funding, and advanced animal testing regulations. However, Asia-Pacific is expected to exhibit the highest growth during the forecast period, driven by increasing investments in research and development, as well as the expanding pharmaceutical and biotechnology sectors in countries like China and India.

Expert Insight: The growing number of research collaborations in Asia-Pacific , paired with government investments in scientific infrastructure, positions this region as a key growth area for the animal model market.

 

Market Trends And Innovation Landscape

The animal model market is poised to witness significant advancements as a result of key trends and innovations aimed at improving the accuracy, cost-efficiency, and ethical considerations of animal-based research. Several technological developments are shaping the landscape, and strategic innovations are setting the stage for future growth.

Advancements in Genetic Engineering

One of the most impactful innovations in the animal model market is the advancement of genetic engineering techniques, such as CRISPR-Cas9, which enables researchers to modify the genetic makeup of animals more precisely. This development has led to the creation of genetically modified animal models that replicate human diseases with higher accuracy, opening new avenues in drug discovery and disease research. The growing emphasis on personalized medicine is further boosting the demand for animal models that are genetically tailored to replicate specific human conditions.

Expert Insight: The increased use of genetically engineered animal models allows researchers to better understand complex diseases, such as Alzheimer’s and Parkinson’s , offering potential breakthroughs in treatment development.

 

Artificial Intelligence (AI) and Machine Learning Integration

The integration of AI and machine learning (ML) technologies into animal model research is transforming the way researchers analyze data and interpret results. AI is being used to enhance predictive modeling, which aids in identifying potential drug candidates and determining the effectiveness of treatments. Furthermore, AI-based systems can analyze animal behavior, physiological changes, and disease progression in real-time, improving the accuracy of the results.

 

3D Modeling and Organ-on-a-Chip Technologies

Innovations in 3D bioprinting and organ-on-a-chip technologies are making it possible to replicate human organ systems in vitro, providing an alternative to traditional animal testing. Although these technologies are still in the early stages of adoption, their potential to reduce the reliance on animal models, especially for drug toxicity testing, is significant. Researchers are exploring ways to integrate organ-on-a-chip systems with animal models to create more comprehensive, human-relevant disease models.

Expert Insight: The future may see a hybrid model where 3D-printed organs and organ-on-a-chip systems complement animal models, reducing the total number of animals used in research while maintaining scientific validity.

 

Regulatory Frameworks and Ethical Considerations

Along with technological advancements, there is a growing focus on ethical considerations and regulatory frameworks aimed at minimizing animal suffering and promoting animal welfare. Countries and regions are adopting more stringent regulations concerning the use of animals in research. For example, the European Union’s Directive 2010/63/EU mandates the reduction, replacement, and refinement of animal testing, encouraging the development of alternatives to animal models. At the same time, global standards are evolving to ensure that animal-based research remains necessary and justifiable.

 

Collaborations and Partnerships

Collaborations between academic institutions, pharmaceutical companies, biotech firms, and CROs are increasing to develop advanced animal models and overcome the limitations of existing models. Such collaborations are critical to ensuring that animal models are used ethically and effectively, while also addressing challenges such as animal welfare concerns and the need for precision models.

Expert Insight: Strategic partnerships between tech companies and research organizations are also likely to increase, particularly as AI, 3D modeling, and genomic tools become more integrated into animal model research.

 

Competitive Intelligence And Benchmarking

The animal model market is highly competitive, with several players striving to advance their product offerings through innovation, partnerships, and expanding their research capabilities. The key players in the market are primarily biotechnology companies, pharmaceutical firms, research organizations, and contract research organizations (CROs). These organizations are engaged in ongoing efforts to enhance the quality of animal models, reduce the ethical burden of animal testing, and provide more accurate results for drug discovery and disease modeling.

Key Players and Their Strategies

Charles River Laboratories International, Inc.

Charles River Laboratories is a global leader in the animal model market, providing comprehensive research services, including animal testing and preclinical services. The company’s strategy revolves around expanding its genetically modified animal models and strengthening its partnerships with pharmaceutical companies and academic institutions. With a broad portfolio of genetically engineered rodents and non-human primates, Charles River aims to support the growing demand for personalized medicine and precision drug development.

 

Envigo

Envigo specializes in providing custom animal models, along with a broad range of research services. The company’s focus on precision animal models is in line with the market’s trend toward more human-relevant disease models. Envigo’s strategy includes increasing its presence in emerging markets and expanding its portfolio of genetically modified animals. The company has also strengthened its partnerships with academic and research organizations to develop advanced models for disease research.

 

The Jackson Laboratory

As a leader in the genetically modified animal model space, The Jackson Laboratory focuses on providing customized animal models for genetic research, disease modeling, and drug discovery. Its strategy includes a robust R&D pipeline aimed at developing new animal strains for a range of diseases. The Jackson Laboratory is also focused on improving genetic precision in its models and expanding its distribution channels across the globe.

 

Taconic Biosciences, Inc .

Taconic Biosciences is another prominent player in the market, offering a wide range of animal models, including genetically engineered and humanized mouse models for cancer, immunology, and neurodegenerative diseases. The company’s competitive edge lies in its focus on providing high-quality animal models with precise genetic modifications. Taconic has also leveraged its strategic collaborations with biopharma companies to advance its research capabilities.

 

Harlan Laboratories (acquired by Covance)

Harlan Laboratories, now part of Covance, is a well-established player in the field of animal models for preclinical and clinical trials. Covance’s strategy focuses on providing in vivo testing and research services across a variety of therapeutic areas, including oncology, toxicology, and immunology. The company’s competitive advantage comes from its ability to integrate animal model testing with contract research services, offering end-to-end solutions for drug discovery.

 

Lonza Group

Lonza is a global player involved in animal model research, particularly focusing on the development of immune-oncology models. Lonza’s strategy emphasizes innovation through bioscience and genetic engineering, ensuring that animal models used for research are more representative of human conditions. The company is also keen on expanding its geographic footprint in regions with high growth potential for research, particularly in Asia-Pacific.

 

Labcorp Drug Development

Labcorp Drug Development offers animal model services as part of its contract research organization services. The company provides a wide variety of animal models and is known for its capabilities in toxicology and drug efficacy testing. Its strategy involves expanding its service offerings, particularly in biomarker discovery, genomic analysis, and personalized medicine, leveraging animal models to develop next-generation therapeutic solutions.

 

Market Positioning and Product Differentiation

These companies differentiate themselves through a variety of strategies:

• Genetic Innovation: Companies like Charles River and Taconic Biosciences are leading the way in offering advanced genetically modified animal models. This allows them to address the rising demand for more specific disease models.

• Customized Solutions: Players such as Envigo and The Jackson Laboratory focus on providing tailored models to meet the specific research needs of pharmaceutical and biotech companies.

• Service Integration: Labcorp Drug Development and Covance provide comprehensive services that integrate animal testing with contract research and clinical trial services, giving them an edge in offering end-to-end solutions.

• Geographical Expansion: Companies are increasingly focusing on expanding their operations into Asia-Pacific, which is expected to be a high-growth region due to the growing pharmaceutical and biotechnology industries in countries like China and India.

 

Regional Landscape And Adoption Outlook

The animal model market is experiencing varying rates of adoption across different regions, driven by factors such as research funding, regulatory frameworks, the presence of pharmaceutical and biotechnology companies, and ethical considerations. The market dynamics in each region are unique, with some areas seeing faster growth than others due to the differing levels of infrastructure, regulatory support, and demand for animal models in drug development.

North America

North America is expected to maintain its dominance in the animal model market, accounting for the largest market share in 2024. This region's strong market position is attributed to the high concentration of pharmaceutical companies, biotech firms, and research institutions, particularly in the United States and Canada. The U.S. remains the global leader in preclinical research, with major companies like Charles River Laboratories and Covance headquartered here, contributing significantly to the market's expansion.

Additionally, the FDA 's support for animal research, along with a favorable regulatory framework for animal testing, ensures that North America continues to be an attractive region for investment in animal model development. The high demand for genetically modified models in North America, particularly for disease modeling and drug discovery, will continue to fuel growth in the market.

Expert Insight: North America's dominance will be sustained by increasing collaboration between pharmaceutical companies and contract research organizations (CROs) , along with a continuous drive toward the refinement of animal models to ensure better precision and efficiency in research.

 

Europe

Europe, driven by stringent ethical standards and regulations around animal testing, will continue to grow at a steady pace, with countries like Germany, the United Kingdom, and France leading the charge. The European Union's regulations on animal welfare, particularly Directive 2010/63/EU, promote the reduction, refinement, and replacement of animals in research, which has resulted in an increasing adoption of advanced animal models and alternatives, such as organ-on-a-chip technologies.

In addition, the presence of major pharmaceutical and biotech companies, along with research grants and funding from the European Commission, supports growth in the region. Despite the regulatory challenges, Europe’s market for animal models is poised to grow as the region focuses on enhancing the human relevancy of animal models.

 

Asia-Pacific

The Asia-Pacific (APAC) region is expected to exhibit the highest growth rate in the animal model market during the forecast period. The expansion of the pharmaceutical and biotechnology sectors, especially in China, India, and Japan, is driving increased demand for animal models. This growth is supported by government investments in R&D and the expansion of life sciences in countries like China, where a rapidly growing market for preclinical research is emerging.

Additionally, APAC has seen increased outsourcing of preclinical testing services to contract research organizations (CROs), with countries like India offering cost-effective alternatives to Western markets. As more research centers and pharmaceutical companies establish a presence in the region, the demand for animal models, particularly for disease research and drug discovery, will continue to rise.

Expert Insight: Asia-Pacific's growth is being driven not only by cost advantages but also by the rapid adoption of genetically modified animal models and an increasingly favorable regulatory environment in countries like China , where animal welfare guidelines are improving.

 

Latin America and Middle East & Africa (LAMEA)

Latin America and Middle East & Africa (LAMEA) are smaller markets in the animal model industry, but they are showing potential for growth due to the increasing focus on healthcare infrastructure and the expanding pharmaceutical and biotechnology sectors in countries like Brazil and South Africa. However, the region still faces challenges related to regulatory standards, ethical concerns, and limited research funding.

In Latin America, countries like Brazil have become key players in the pharmaceutical market, which is expected to drive demand for animal models used in preclinical studies. Meanwhile, in the Middle East, Saudi Arabia and the UAE are investing heavily in healthcare and life sciences, and research hubs are emerging, increasing the demand for animal model solutions.

 

End-User Dynamics And Use Case

The animal model market is influenced by a diverse range of end-users, each with unique demands and applications for animal models in their research and product development processes. These end-users include pharmaceutical companies, biotechnology firms, academic and research institutions, contract research organizations (CROs), and government agencies. Each sector plays a vital role in driving the market by leveraging animal models to support drug discovery, disease research, and regulatory testing.

Pharmaceutical Companies

Pharmaceutical companies are the largest end-users of animal models, as they rely on these models for various stages of drug development, from preclinical testing to regulatory approval. These companies use animal models for toxicology studies, efficacy testing, and drug metabolism research. The demand for genetically modified animal models has increased, particularly in oncology, immunology, and neurological disorder research.

 

Biotechnology Firms

Biotechnology companies also rely heavily on animal models for developing new therapeutics, especially in areas like gene therapy, biologics, and monoclonal antibodies. These firms are increasingly adopting advanced models to better simulate human diseases and improve the accuracy of their experimental results. Biotechnology companies often focus on high-fidelity models, such as humanized mouse models, to test novel therapies and ensure their safety and efficacy.

 

Academic and Research Institutions

Academic and research institutions use animal models primarily for fundamental research and discovery-driven studies. These institutions are key drivers of innovation in animal model development, particularly in areas like genetics, neuroscience, and infectious disease research. Collaboration between academic institutions and private companies is fostering the development of more precise and relevant animal models, advancing the understanding of complex diseases.

 

Contract Research Organizations (CROs)

CROs provide preclinical testing services for pharmaceutical and biotechnology companies. These organizations are crucial in offering outsourced research services, including animal model-based studies, such as pharmacokinetics, toxicology assessments, and efficacy trials. The rising outsourcing of preclinical trials is expected to continue driving demand for animal models, particularly in regions like Asia-Pacific where CROs offer competitive pricing.

 

Government Agencies and Regulatory Bodies

Government agencies, such as the FDA and European Medicines Agency (EMA), oversee the ethical and regulatory aspects of animal model use in research. These agencies require animal testing for the approval of new drugs, vaccines, and medical devices. The demand for animal models will remain high in regulatory applications, especially as global regulations surrounding animal testing evolve to ensure ethical standards.

 

Use Case: Pharmaceutical Research at a Major Oncology Company

A leading oncology pharmaceutical company in the United States recently used a genetically modified mouse model to study the efficacy of a new cancer immunotherapy. The company had previously struggled with the development of accurate models to assess the immune response to novel treatments. However, by utilizing a humanized mouse model, which replicates human immune systems, the researchers were able to evaluate the therapeutic effects of the drug in a way that closely mimicked human biology.

This research led to promising findings, demonstrating a significant reduction in tumor growth. The use of the animal model accelerated the company's preclinical development timeline and provided more reliable data for regulatory approval. The company is now planning to move the therapy into clinical trials based on the success of the animal model study.

Expert Insight: The growing complexity of diseases like cancer and neurological disorders has led to increased reliance on advanced animal models, particularly those that are genetically engineered to mirror human conditions more accurately.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

The animal model market has witnessed several important developments over the past two years, including advancements in genetic modification techniques, regulatory updates, and new collaborations in the research space. Key events include:

• FDA Approval of Advanced Genetic Models for Oncology Research: In the past year, the FDA approved the use of genetically modified animal models, specifically humanized mouse models, for cancer immunotherapy studies. This approval is a significant milestone, as it encourages the use of more relevant, human-like models in preclinical drug development, improving the accuracy and predictive value of preclinical trials.

• Partnership Between Charles River Laboratories and CRISPR Therapeutics: Charles River Laboratories, a leading player in the animal model market, entered into a strategic partnership with CRISPR Therapeutics to develop gene-edited animal models. This collaboration aims to leverage CRISPR-Cas9 gene editing technology to create animal models that more precisely reflect human genetic diseases, particularly those related to neurodegenerative diseases and genetic disorders.

• Launch of a New Range of Customizable Animal Models by Envigo: Envigo launched a new line of customizable animal models designed specifically for the biotechnology and pharmaceutical sectors. These models are engineered to replicate various human diseases with a high degree of accuracy, providing pharmaceutical companies with more reliable models for drug discovery and testing.

 

Opportunities

• Expansion in Emerging Markets: Emerging markets, particularly in Asia-Pacific, offer significant growth opportunities for the animal model market. The rapid expansion of the biopharmaceutical sector, coupled with increasing investments in research infrastructure in countries like China, India, and South Korea, is expected to drive demand for animal models. As these regions continue to invest in genetic engineering and drug discovery, the adoption of animal models will grow.

• Adoption of AI and Automation in Animal Research: The integration of artificial intelligence (AI) and automation in animal model research presents a major opportunity. AI-driven data analysis and automation in animal testing can improve efficiency, reduce costs, and provide more precise results. These technologies are expected to streamline the development of new animal models and enhance the overall research process.

• Increasing Demand for Personalized Medicine: The growing trend towards personalized medicine presents a significant opportunity for animal models, particularly genetically modified models. As drug developers shift toward treatments tailored to individual genetic profiles, there is an increasing need for animal models that replicate human diseases with high fidelity. Personalized animal models can help bridge the gap between preclinical research and human clinical trials.

 

Restraints

• Regulatory Delays and Ethical Concerns: Despite advancements in animal model development, the market faces challenges from regulatory delays and ethical concerns around the use of animals in research. Stricter regulations in regions like the European Union, which mandate the reduction, refinement, and replacement of animal testing, may slow market growth. Furthermore, the growing public concern over animal welfare can lead to restrictions on animal use in research, particularly in developed regions.

• High Cost of Animal Models and Research: The cost of developing genetically modified animal models and maintaining animal research facilities can be prohibitively high. Smaller research organizations and biotechnology companies may face financial barriers to accessing these advanced models, limiting their ability to conduct high-quality research. Additionally, the need for specialized expertise in handling and breeding genetically engineered animals further drives up costs.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 2.5 Billion
Revenue Forecast in 2030	USD 4.5 Billion
Overall Growth Rate CAGR	10.5% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Animal Type, By Application, By End User, By Region
By Animal Type	Mice, Rats, Pigs, Non-Human Primates, Others
By Application	Toxicology Testing, Disease Research, Drug Discovery, Others
By End User	Pharmaceutical Companies, Biotechnology Firms, Academic and Research Institutions, CROs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	United States, United Kingdom, Germany, China, India, Japan, Brazil, etc.
Market Drivers	Technological advancements, rising chronic disease prevalence, regulatory support
Customization Option	Available upon request